Prosecution Insights
Last updated: November 04, 2026
Application No. 18/795,117

METHODS FOR SINGLE MOLECULE SEQUENCING

Non-Final OA §102§103§112§DOUBLEPATENT
Filed
Aug 05, 2024
Priority
Mar 13, 2018 — provisional 62/642,373 +2 more
Examiner
WOOLWINE, SAMUEL C
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sarmal Inc.
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
1y 4m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
529 granted / 867 resolved
+1.0% vs TC avg
Strong +20% interview lift
Without
With
+20.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
47 currently pending
Career history
926
Total Applications
across all art units

Statute-Specific Performance

§101
6.2%
-33.8% vs TC avg
§103
37.0%
-3.0% vs TC avg
§102
14.2%
-25.8% vs TC avg
§112
29.9%
-10.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 867 resolved cases

Office Action

§102 §103 §112 §DOUBLEPATENT
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 19 and 20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. These claims depend from claims 18 and 17, respectively, which have been cancelled. Therefore, as the scope of the claims is not certain, the examiner has not attempted to examine these claims over the prior art. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-6, 8-13, 21 and 23 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Fuller (US 7,264,934 issued Sep. 4, 2017, IDS ref). Claim interpretation: Instant claims recited with alternating term “or” “and/or” has been interpreted as to require single limitation. Regarding instant claim 1, Fuller teaches a reaction and detection scheme for sequencing by the new, stepwise method with pyrophosphate detection. FIG. 10A shows the reaction of an individual bead when one of four nucleotides is added to the reaction system. In the absence of divalent cation, polymerase forms a stable, closed-complex with the nucleotide (e.g. dATP) that complements the next template nucleotide (e.g. T, partial template sequence shown: 5'-GCTTTTTCT-3' (SEQ ID NO: 6)). Excess nucleotide is washed away. Then divalent cation is introduced along with other detection reagents and detection is performed, as an example, by the detection of photons generated from the Luciferase reaction through a succession of enzymatic steps. It is noted that because a closed-complex only forms with a complementary nucleotide, each cycle adds at most one nucleotide to the growing chain. FIG. 10B shows an alternative to FIG. 10A. Here terminal phosphate-labeled nucleotides are each labeled with a distinct label. In this way, all four nucleotide bases can be added in the same reaction mixture such that the next base of all the templates can be identified in a single round of polymerase reaction (Column 17, paragraphs 3-6, column 18, paragraph 1). PNG media_image1.png 456 618 media_image1.png Greyscale The teachings of Fuller as discussed above meets the limitations of claim 1 of method for sequencing a nucleic acid template comprising: providing a sequencing mixture comprising (i) a polymerase enzyme (Fig. 10 A), (ii) an ATP regenerating enzyme, (iii) a luminescence enzyme (i.e., luciferase), (iv) a template nucleic acid, and (iii) a polymerase-ATP regenerating enzyme-luminescence reagent solution having the components for carrying out template directed synthesis of a growing nucleic acid strand, wherein said reagent solution includes an ATP-regenerating-enzyme-substrate (APS, a luminescence-substrate; and a plurality of types of nucleotide analogs; wherein each type of nucleotide analog has a labeled leaving group that is cleavable by the polymerase, and each type of nucleotide analog has a different label, wherein the labeled leaving group is cleaved upon polymerase-dependent binding of a respective nucleotide analog to the template strand; carrying out nucleic acid synthesis such that a plurality of nucleotide analogs are added sequentially to the template whereby: a) a nucleotide analog associates with the polymerase, b) the nucleotide analog is incorporated on the template strand by the polymerase when the labeled leaving group on that nucleotide analog is cleaved by the polymerase, wherein the labeled leaving group is combined with an ATP-regenerating-enzyme-substrate by the ATP regenerating enzyme yielding labeled-ATP, then c) binding the labeled-ATP to a luminescence-enzyme, wherein a luminescence-substrate is catalyzed by the luminescence-enzyme to produce luminescence for a limited period of time and regenerate the respective labeled leaving group, wherein said luminescence causes the label on the respective labeled leaving group to produce light; and detecting light from the labels while nucleic acid synthesis is occurring, and using light detected during each discreet luminescence period, to determine a sequence of the template nucleic acid. Regarding claim 2, Fuller teaches that the nucleotide analog has been modified by a fluorophore attached to a terminal phosphate (Fig. 1). Regarding claims 3 and 4, Fuller teaches that the leaving group is a dye labelled pyrophosphate (column 2, line 53, Fuller claim 19). Regarding claim 5, Fuller teaches that the each base of a nucleotide is labeled with a unique fluorophore relative to other bases (Fig. 4) Regarding claim 6, Fuller teaches luciferase enzyme (Fig. 10A). Regarding claim 8, Fuller teaches luciferin (Fig. 10A). Regarding claim 9, Fuller teaches a DNA polymerase (column 5, line 1) Regarding claim 10, Fuller teaches ATP Sulfurylase (Fuller, claim 22). Regarding claims 11 and 12, Fuller teaches ATP Sulfurylase (i.e., APS; Fuller, claim 22). Regarding claim 13, Fuller teaches dATP (Fuller, Fig. 10 A). Regarding claims 21 and 23, Fuller teaches a DNA polymerase I and DNA polymerase II (column 5, lies 1-3), which meets the limitation of said claims of plurality of enzymes recited in generality. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 7 and 14-16 are rejected under 35 U.S.C. 103 as being unpatentable over Fuller (US 7,264,934 issued Sep. 4, 2017, IDS ref) in view of Marques et al (Anal Bioanal Chem 2008 published 2008, 391, 2161-2168, IDS ref). Fuller and Marques teach a pyrosequencing method using luciferase and therefore are analogous arts. Fuller teaches luciferase (Fig. 10A) but does not specifically teach that the luciferase is firefly luciferase, which is taught by Marques, who is in the same field of endeavor teaches an optimized luciferase bioluminescent assay for coenzyme A quantification (Abstract) and further teaches that the firefly luciferase, which causes a flash of light that can be measured in a luminometer (Abstract). The artisan having ordinary skill in the art would recognize that firefly luciferase is routinely used especially in the pyrosequencing field as further evidenced by Ju et al (US 9,909,177 issued Mar. 6, 2018, effective filing dateJun.21, 2005, column 1, paragraph 4). Regarding claim 14, Fuller in view of Marques teaches reaction mixture comprises pyrophosphatase enzyme (Marques, pg.2167, column 2, paragraph 1), which is capable of converting pyrophosphate into 2 phosphate ions. Regarding claim 15, requiring the limitation of the ratios of enzyme on concentrations are adjusted such that ATP sulfurylase/Luciferase loop activity is orders of magnitude higher than the pyrophosphatase activity, the artisan having ordinary skill in the art would recognize that amount to routine optimization and thus would be an obvious improvement over Fuller in view of Marques. Regarding claim 16, requiring the limitation of relative reaction rate of ATP Sulfurylase/Luciferase loop, Fuller teaches an ATP Sulfurylase/Luciferase loop (Fig. 10A). The artisan would recognize the limitation of is selected from the group consisting of at least: to 102 times faster than the pyrophosphatase reaction amounts to routine optimization and thus would be an obvious improvement over Fuller in view of Marques. As discussed above, both Fuller and Marques teach luciferase and Marques teaches that firefly luciferase allows detection of coenzyme A, which is an ubiquitous organic substance that is essential for many biological processes, as it acts as a transient carrier of acyl groups in enzymatic reactions (Introduction section paragraph 1) thereby providing teachings, suggestions and motivation to include fire fly luciferase in the method of Fuller. It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention was made to include the firefly luciferase in place of generic luciferase with a reasonable expectation of success with the expected benefit of increasing the utilities of the method of Fuller as taught by Marques. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-16, 19-21 and 23 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 12,054,772. Although the claims at issue are not identical, they are not patentably distinct from each other because the ‘772 claims disclose all limitations of the instant claims, thereby anticipating the instant claims and rendering them obvious. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAMUEL C WOOLWINE whose telephone number is (571)272-1144. The examiner can normally be reached 9am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, GARY BENZION can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAMUEL C WOOLWINE/Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Aug 05, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781260
SINGLE-STRAND BINDING PROTEIN
4y 2m to grant Granted Nov 03, 2026
Patent 12781279
OLIGONUCLEOTIDES ASSOCIATED WITH ANTIBODIES
3y 7m to grant Granted Nov 03, 2026
Patent 12766517
Nano-PCR: Methods and Devices for Nucleic Acid Amplification and Detection
12y 10m to grant Granted Oct 20, 2026
Patent 12767981
NUCLEIC ACID SEQUENCE MEASUREMENT METHOD AND NUCLEIC ACID SEQUENCE MEASUREMENT KIT
3y 7m to grant Granted Oct 20, 2026
Patent 12736529
STREPTAVIDIN-COATED SOLID PHASES WITH A MEMBER OF A BINDING PAIR
5y 4m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
81%
With Interview (+20.3%)
3y 7m (~1y 4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 867 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month